Chunyan Lan1,2, Jingxian Shen2,3, Yin Wang1,2, Jundong Li1,2, Zhimin Liu1,2, Mian He4, Xinping Cao2,5, Jiayu Ling6, Jiaming Huang4, Min Zheng1,2, Guorong Zou7, Haowen Yan7, Qing Liu2,8, Fan Yang1,2, Wei Wei1,2, Yanhong Deng6, Ying Xiong1,2, Xin Huang1,2. 1. Department of Gynecologic Oncology, Sun Yat-sen University Cancer Centre, Guangzhou, China. 2. State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China. 3. Department of Radiology, Sun Yat-sen University Cancer Centre, Guangzhou, China. 4. Department of Obstetrics and Gynecology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. 5. Department of Radiotherapy, Sun Yat-sen University Cancer Centre, Guangzhou, China. 6. Department of Medical Oncology, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. 7. Department of Radiotherapy, Panyu Central Hospital, Guangzhou, China. 8. Department of Cancer Prevention Centre, Sun Yat-sen University Cancer Centre, Guangzhou, China.
Abstract
PURPOSE: Camrelizumab is an antibody against programmed death protein 1. We assessed the activity and safety of camrelizumab plus apatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, in patients with advanced cervical cancer. METHODS: This multicenter, open-label, single-arm, phase II study enrolled patients with advanced cervical cancer who progressed after at least one line of systemic therapy. Patients received camrelizumab 200 mg every 2 weeks and apatinib 250 mg once per day. The primary end point was objective response rate (ORR) assessed by investigators per RECIST version 1.1. Key secondary end points were progression-free survival (PFS), overall survival (OS), duration of response, and safety. RESULTS: Forty-five patients were enrolled and received treatment. Median age was 51.0 years (range, 33-67 years), and 57.8% of patients had previously received two or more lines of chemotherapy for recurrent or metastatic disease. Ten patients (22.2%) had received bevacizumab. Median follow-up was 11.3 months (range, 1.0-15.5 months). ORR was 55.6% (95% CI, 40.0% to 70.4%), with two complete and 23 partial responses. Median PFS was 8.8 months (95% CI, 5.6 months to not estimable). Median duration of response and median OS were not reached. Treatment-related grade 3 or 4 adverse events (AEs) occurred in 71.1% of patients, and the most common AEs were hypertension (24.4%), anemia (20.0%), and fatigue (15.6%). The most common potential immune-related AEs included grade 1-2 hypothyroidism (22.2%) and reactive cutaneous capillary endothelial proliferation (8.9%). CONCLUSION: Camrelizumab plus apatinib had promising antitumor activity and manageable toxicities in patients with advanced cervical cancer. Larger randomized controlled trials are warranted to validate our findings.
PURPOSE: Camrelizumab is an antibody against programmed death protein 1. We assessed the activity and safety of camrelizumab plus apatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, in patients with advanced cervical cancer. METHODS: This multicenter, open-label, single-arm, phase II study enrolled patients with advanced cervical cancer who progressed after at least one line of systemic therapy. Patients received camrelizumab 200 mg every 2 weeks and apatinib 250 mg once per day. The primary end point was objective response rate (ORR) assessed by investigators per RECIST version 1.1. Key secondary end points were progression-free survival (PFS), overall survival (OS), duration of response, and safety. RESULTS: Forty-five patients were enrolled and received treatment. Median age was 51.0 years (range, 33-67 years), and 57.8% of patients had previously received two or more lines of chemotherapy for recurrent or metastatic disease. Ten patients (22.2%) had received bevacizumab. Median follow-up was 11.3 months (range, 1.0-15.5 months). ORR was 55.6% (95% CI, 40.0% to 70.4%), with two complete and 23 partial responses. Median PFS was 8.8 months (95% CI, 5.6 months to not estimable). Median duration of response and median OS were not reached. Treatment-related grade 3 or 4 adverse events (AEs) occurred in 71.1% of patients, and the most common AEs were hypertension (24.4%), anemia (20.0%), and fatigue (15.6%). The most common potential immune-related AEs included grade 1-2 hypothyroidism (22.2%) and reactive cutaneous capillary endothelial proliferation (8.9%). CONCLUSION: Camrelizumab plus apatinib had promising antitumor activity and manageable toxicities in patients with advanced cervical cancer. Larger randomized controlled trials are warranted to validate our findings.
Authors: Hyun Cheol Chung; Willeke Ros; Jean-Pierre Delord; Ruth Perets; Antoine Italiano; Ronnie Shapira-Frommer; Lyudmila Manzuk; Sarina A Piha-Paul; Lei Xu; Susan Zeigenfuss; Scott K Pruitt; Alexandra Leary Journal: J Clin Oncol Date: 2019-04-03 Impact factor: 44.544
Authors: Emeka K Enwere; Elizabeth N Kornaga; Michelle Dean; Theodora A Koulis; Tien Phan; Maria Kalantarian; Martin Köbel; Prafull Ghatage; Anthony M Magliocco; Susan P Lees-Miller; Corinne M Doll Journal: Mod Pathol Date: 2017-01-06 Impact factor: 7.842
Authors: David S Alberts; John A Blessing; Lisa M Landrum; David P Warshal; Lainie P Martin; Stephen L Rose; Albert J Bonebrake; Lois M Ramondetta Journal: Gynecol Oncol Date: 2012-09-14 Impact factor: 5.482
Authors: Yong Qin; Suhendan Ekmekcioglu; Marie-Andrée Forget; Lorant Szekvolgyi; Patrick Hwu; Elizabeth A Grimm; Amir A Jazaeri; Jason Roszik Journal: Front Immunol Date: 2017-06-16 Impact factor: 7.561
Authors: Zowi R Huinen; Elisabeth J M Huijbers; Judy R van Beijnum; Patrycja Nowak-Sliwinska; Arjan W Griffioen Journal: Nat Rev Clin Oncol Date: 2021-04-08 Impact factor: 66.675